FILTER
LATEST INTERVIEWS
James Hume
PRESIDENT, EAGLE MAPPING
Eagle Mapping are busy Lidar scanning the northern parts of B.C. and Yukon from the air.
Stephen Keith
PRESIDENT, GROWMAX RESOURCES
Recently re-branded GrowMax Resources explains how it intend to develop its fertilizer assets in Peru.
Dr. Hany Moustapha
PROFESSOR AND DIRECTOR, AÉROÉTS & ENIOR RESEARCH FELLOW PWC
École de technologie supérieure (ÉTS) is Canada’s leading university when it comes to aerospace graduating 750-800 engineers each year.
Gilles Labbé
PRESIDENT & CEO, HÉROUX-DEVTEK
Héroux-Devtek continues to grow its landing gear business with its contract for Boeing’s 777.
Dale Clayton
MANAGING DIRECTOR, LIEBHERR
Lieberr sees Chile as a good opportunity to diversify its commodity exposure and is building a firm presence there.
Ivan Rayo
GENERAL MANAGER, JRI INGENIERÍA
Chilean engineering company JRI describes how experience and innovation have helped the company to expand.
Christian Kopfli
CEO, CHROMOCELL
Chromocell is using its own Chrmovert technology to provide alternative pain blockers to opioids.
Renold Capocasale
CEO, FLOWMETRIC INC.
FlowMetric offers scientific analysis using Flow Cytometry to advance drug development.
Martin Staples
DIRECTOR, AMC CONSULTANTS
AMC Consultants describe how the company managed the downturn and some of its implications for Western Australian mining.
Robert Archer
PRESIDENT & CEO, GREAT PANTHER SILVER
Great Panther Silver made a foray into Peru last year with the acquisition of the Coricancha mine complex which it intends to bring to production swiftly.
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
United States Life Sciences 2025 - Digital Interactive
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
